Sign in Subscribe
Antiretroviral agents

HIV/AIDS Management and Prevention: A New Frontier in Cardiovascular Disease Management

Strategic Insights

— 1 min read

Current study results indicate that HIV/AIDS patients are disproportionately affected by cardiovascular diseases (CVDs) despite effective viral load suppression with antiretroviral therapy (ART). The mechanisms underlying this relationship are complex and incompletely understood, involving a interplay of traditional cardiovascular risk factors, chronic inflammation, and metabolic side effects of ART. Recent trials have shed light on interventions such as early initiation of statin therapy to mitigate systemic inflammation and improve cardiovascular outcomes.

Key Takeaways:

  • The prevalence and development of CVD in HIV patients are critical areas of concern, impacting morbidity and mortality despite effective ART.
  • The optimal strategy for primary and secondary prevention of CVD in HIV patients remains unclear, but early initiation of statin therapy has shown promise in mitigating systemic inflammation and improving cardiovascular outcomes.
  • Traditional cardiovascular risk factors, chronic inflammation, and metabolic side effects of ART contribute to the increased risk of CVD in HIV patients.
  • Tools for assessing cardiovascular risk in the general population perform inconsistently in HIV patients, highlighting the need for unique approaches to management.
  • Recent trials have demonstrated the importance of considering the interplay between HIV infection, ART, and atherosclerotic disease in managing CVD.

The news editors report that additional information may be obtained by contacting Sandhya Limaye, Concord Clinical School, University of Sydney, Camperdown, New South Wales, Australia. Additional authors for this research include Jack Kerferd and Sonali R. Gnanenthiran.

Statistics:

  • According to the research, cardiovascular diseases disproportionately affect people with HIV (PWH), impacting morbidity and mortality, even with effective viral load suppression with ART.
  • Recent trials have shown that early initiation of statin therapy can mitigate systemic inflammation and improve cardiovascular outcomes in HIV patients.
  • The prevalence and development of CVD in HIV patients are critical areas of concern due to their impact on morbidity and mortality.

Sources:

  • Internal Medicine Journal, 2025
  • NewsRx. New HIV/AIDS Data Have Been Reported by Researchers at University of Sydney (Cardiovascular disease management and prevention: the new frontier in the management of patients with human immunodeficiency virus infection). AIDS Weekly. November 3, 2025; p 47.
  • Wiley. Internal Medicine Journal. 111 River St, Hoboken 07030-5774, NJ, USA.
  • University of Sydney, Concord Clinical School, Camperdown, New South Wales, Australia.

Read more